|
Chinese expert consensus on the diagnosis and treatment of children with idiopathic short stature
The Subspecialty Group of Endocrinology, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association, Adolescent Health and Medical Professional Committee, Chinese Medical Doctor Association, Futang Research Center of Pediatric Development, et al
2023, 38(11):
801-813.
DOI: 10.19538/j.ek2023110601
Idiopathic short stature(ISS)is a group of highly heterogeneous disorders that cause short stature but have no known etiology. ISS describes a state of short stature of unknown causes. To diagnose ISS,clinicians should exclude all known diseases by a complete evaluation,which is based on a combination of clinical history,physical examination,complete routine and endocrine laboratory tests and imaging examinations,and genetic testing with informed consent(recommend). After a comprehensive and systematic diagnostic evaluation,the short stature still with unknown causes is defined as ISS. The treatment of ISS should involve the pediatric endocrinologist and the child's family in the decision-making of the treatment plan and course of treatment. In 2021,China's National Medical Products Administration (NMPA) approved human growth hormone (hGH) treatment for ISS. Treatment is recommended to be adjusted according to the growth response (the rate of height growth). Gonadotropin-releasing hormone analogues (GnRHa) or aromatase inhibitors or recombinant insulin-like growth factor-1 (rhIGF-1) in combination with hGH are insufficient in evidence-based evidence for the treatment of ISS and are not recommended for routine use.
|